MS drug
Boards of Appeal revoke Biogen's dosage patent for Tecfidera
The Boards of Appeal at the European Patent Office have refused to grant Biogen's dosage patent EP 873, which is central to its multiple sclerosis drug Tecfidera. This decision resolves several PI and
...
12 December 2025 by Mathieu Klos
